Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.

Investigational Treatment Regimen Could Expand Options for Virologically Suppressed Adults –– Positive Phase 3 Results from ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Gilead Sciences, Inc. (NASDAQ:GILD) stock is about to trade ex-dividend in 4 days. The ex-dividend date is one business day ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best pharma stocks to invest in. Cantor Fitzgerald analyst Carter Gould ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

Gilead Sciences Inc.’s experimental twice-yearly shot prevented 100% of HIV cases in women and adolescent girls in Africa, the first successful big trial of what’s hoped to become a powerful new drug ...

We recently published a list of 10 Stocks That Analysts Think Will Go Up. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other stocks that ...

Inflation, interest rates, and broader economic uncertainty have forced companies across many sectors to prioritize ...

A new drug that gives almost complete protection against the virus was to be administered across Africa this year. Now, much of the funding for that effort is gone. By Stephanie Nolen The drug could ...

U.S. sues Gilead over role in developing HIV-prevention drug Govt broke pacts with Gilead when it applied for patents -court (Reuters) - A Washington, D.C. federal court said in a decision made public ...

The stock's rise snapped a four-day losing streak.